Oncotargets in different renal cancer subtypes

Current Drug Targets

Volumn 16, Issue 2, 2015, Pages 125-135

  Moch, Holger ^a   Montironi, Rodolfo ^b   Lopez Beltran, Antonio ^c   Cheng, Liang ^d   Mischo, Axel ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c Universidad de Cordoba   (Spain)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical trials; Personalized medicine; Renal cancer; Targeted therapy

Indexed keywords

ALPHA INTERFERON; AXITINIB; B7 ANTIGEN; BEVACIZUMAB; CD70 ANTIGEN; CD86 ANTIGEN; EVEROLIMUS; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MONOCLONAL ANTIBODY; PAZOPANIB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUCCINATE DEHYDROGENASE; SUNITINIB; TEMSIROLIMUS; TIVOZANIB; VASCULOTROPIN; ANTINEOPLASTIC AGENT;

ANGIOGENESIS; ANGIOMYOLIPOMA; ARTICLE; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CHROMOSOME 3P; COMPLEX II DEFICIENCY; COWDEN SYNDROME; DRUG TOLERABILITY; GENE EXPRESSION; GENE MUTATION; GENE PRODUCT; GENETIC HETEROGENEITY; HEMANGIOBLASTOMA; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHEOCHROMOCYTOMA; PREVALENCE; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; TUMOR SUPPRESSOR GENE; UPREGULATION; VON HIPPEL LINDAU DISEASE; CARCINOMA, RENAL CELL; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; GENETICS; KIDNEY NEOPLASMS; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PROCEDURES; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; HUMANS; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION;

EID: 84924293132     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450116666150126110632     Document Type: Article

References (134)

1. Frew IJ, Moch H. A clearer view of the molecular complexity of clear cell renal cell carcinoma. Annu Rev Pathol Mech Dis 2015; 10: 263-289
2. Moch H. (2014). Kidney Cancer. In: Stewart BW and Wild CP, eds. World Cancer Report 2014. (Lyon: World Health Organization International Agency for Research on Cancer (IARC)), pp. 2-9
3. Srigley JR, Delahunt B, Eble JN, et al. The international society of urological pathology (isup) vancouver classification of renal neoplasia. Am J Surg Pathol 2013; 37(10): 1469-1489
4. Moch H. An overview of renal cell cancer: pathology and genetics. Semin Cancer Biol 2013; 23(1): 3-9
5. Guo J, Tretiakova MS, Troxell ML, et al. Tuberous Sclerosisassociated Renal Cell Carcinoma: A Clinicopathologic Study of 57 Separate Carcinomas in 18 Patients. Am J Surg Pathol 2014; 38(11):1457-1467
6. Gill AJ, Hes O, Papathomas T, et al. Succinate Dehydrogenase (SDH)-deficient Renal Carcinoma: A Morphologically Distinct Entity: A Clinicopathologic Series of 36 Tumors From 27 Patients. Am J Surg Pathol 2014; 38(12): 1588-1602
7. Shuch B, Ricketts CJ, Vocke CD, et al. Germline PTEN Mutation Cowden Syndrome: An Under-Appreciated Form of Hereditary Kidney Cancer. J Urol 2013; 190(6): 1990-1998
8. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013; 499(7456): 43-49
9. Shen C and Kaelin WG, Jr. The VHL/HIF axis in clear cell renal carcinoma. Semin Cancer Biol 2013; 23(1): 18-25
10. Farley MN, Schmidt LS, Mester JL, et al. Germline BAP1 mutation predisposes to familial clear-cell renal cell carcinoma. Mol Cancer Res 2013; 11(9): 1061-1071
11. Pena-Llopis S, Vega-Rubin-de-Celis S, Liao A, et al. BAP1 loss defines a new class of renal cell carcinoma. Nat Genet 2012; 44(7): 751-759
12. Varela I, Tarpey P, Raine K, et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 2011; 469(7331): 539-542
13. Dalgliesh GL, Furge K, Greenman C, et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 2010; 463(7279): 360-363
14. Linehan WM, Ricketts CJ. The metabolic basis of kidney cancer. Semin Cancer Biol 2013; 23(1): 46-55
15. Fisher R, Gore M, Larkin J. Current and future systemic treatments for renal cell carcinoma. Semin Cancer Biol 2013; 23(1): 38-45
16. Tan PH, Cheng L, Rioux-Leclercq N, et al. Renal tumors: diagnostic and prognostic biomarkers. Am J Surg Pathol 2013; 37(10): 1518-1531
17. Moch H, Gasser T, Amin MB, Torhorst J, Sauter G, Mihatsch MJ. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer 2000; 89(3): 604-614
18. Zbar B, Brauch H, Talmadge C, Linehan M. Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. Nature 1987; 327: 721-727
19. Seizinger BR, Rouleau GA, Ozelius LJ, et al. Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 1988; 332(6161): 268-269
20. Kovacs G, Erlandsson R, Boldog F, et al. Consistent chromosome 3p deletion and loss of heterozygosity in renal cell carcinoma. Proc Natl Acad Sci USA 1988; 85(5): 1571-1575
21. Frew IJ, Thoma CR, Georgiev S, et al. pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation. Embo J 2008; 27(12): 1747-1757
22. Albers J, Rajski M, Schonenberger D, et al. Combined mutation of Vhl and Trp53 causes renal cysts and tumours in mice. EMBO Mol Med 2013; 5(6): 949-964
23. Beroukhim R, Brunet JP, Di Napoli A, et al. Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res 2009; 69(11): 4674-4681
24. Shen C, Beroukhim R, Schumacher SE, et al. Genetic and functional studies implicate HIF1alpha as a 14q kidney cancer suppressor gene. Cancer Discov 2011; 1(3): 222-235
25. Schraml P, Struckmann K, Bednar R, et al. CDKNA2A mutation analysis, protein expression, and deletion mapping of chromosome 9p in conventional clear-cell renal carcinomas: evidence for a second tumor suppressor gene proximal to CDKN2A. Am J Pathol 2001; 158(2): 593-601
26. Kapur P, Pena-Llopis S, Christie A, et al. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Lancet Oncol 2013; 14(2): 159-167
27. Gossage L, Murtaza M, Slatter AF, et al. Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma. Genes Chromosomes Cancer 2014; 53(1): 38-51
28. Frew IJ, Krek W. pVHL: a multipurpose adaptor protein. Sci Signal 2008; 1(24): pe30
29. Rechsteiner MP, von Teichman A, Nowicka A, Sulser T, Schraml P, Moch H. VHL gene mutations and their effects on hypoxia inducible factor HIFalpha: identification of potential driver and passenger mutations. Cancer Res 2011; 71(16): 5500-5511
30. Lee K, Zhang H, Qian DZ, Rey S, Liu JO, Semenza GL. Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proc Natl Acad Sci USA 2009; 106(42): 17910-17915
31. Kim WY, Kaelin WG, Jr. Molecular pathways in renal cell carcinoma--rationale for targeted treatment. Semin Oncol 2006; 33(5): 588-595
32. Brugarolas J. Renal-cell carcinoma--molecular pathways and therapies. N Engl J Med 2007; 356(2): 185-187
33. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370(9605): 2103-2111
34. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356(2): 125-134
35. Ramp U, Jaquet K, Reinecke P, et al. Functional intactness of stimulatory and inhibitory autocrine loops in human renal carcinoma cell lines of the clear cell type. J Urol 1997; 157(6): 2345-2350
36. Moch H, Sauter G, Buchholz N, et al. Epidermal growth factor receptor expression is associated with rapid tumor cell proliferation in renal cell carcinoma. Hum Pathol 1997; 28(11): 1255-1259
37. Minner S, Rump D, Tennstedt P, et al. Epidermal growth factor receptor protein expression and genomic alterations in renal cell carcinoma. Cancer 2012; 118(5): 1268-1275
38. Moch H, Sauter G, Gasser T, et al. EGF-r gene copy number gains detected by fluorescence in situ hybridization in renal cell carcinoma. J Pathol 1998; 184: 424-429
39. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372(9637): 449-456
40. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28(6): 1061-1068
41. Boysen G, Bausch-Fluck D, Thoma CR, et al. Identification and functional characterization of pVHL-dependent cell surface proteins in renal cell carcinoma. Neoplasia 2012; 14(6): 535-546
42. Ruf M, Mittman C, Nowicka AM, et al. pVHL/HIF-Regulated CD70 Expression Is Associated with Infiltration of CD27þ Lymphocytes and Increased Serum Levels of Soluble CD27 in Clear Cell Renal Cell Carcinoma. Clinical Cancer Res. in press.
43. Jiang F, Richter J, Schraml P, et al. Chromosomal imbalances in papillary renal cell carcinoma: Genetic differences between histologic subtypes. Am J Pathol 1998; 153(5): 1467-1473
44. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET protooncogene in papillary renal carcinomas. Nat Genet 1997; 16(1): 68-73
45. Choueiri TK, Vaishampayan U, Rosenberg JE, et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol 2013; 31(2): 181-186
46. Zbar B, Alvord WG, Glenn G, et al. Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dube syndrome. Cancer Epidemiol Biomarkers Prev 2002; 11(4): 393-400
47. Hasumi H, Baba M, Hong SB, et al. Identification and characterization of a novel folliculin-interacting protein FNIP2. Gene 2008; 415(1-2): 60-67
48. Nickerson ML, Warren MB, Toro JR, et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. Cancer Cell 2002; 2(2): 157-164
49. Hasumi Y, Baba M, Ajima R, et al. Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2. Proc Natl Acad Sci USA 2009; 106(44): 18722-18727
50. Baba M, Hong SB, Sharma N, et al. Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc Natl Acad Sci USA 2006; 103(42): 15552-15557
51. Argani P, Antonescu CR, Illei PB, et al. Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. Am J Pathol 2001; 159(1): 179-192
52. Argani P, Hawkins A, Griffin CA, et al. A distinctive pediatric renal neoplasm characterized by epithelioid morphology, basement membrane production, focal HMB45 immunoreactivity, and t(6;11)(p21.1;q12) chromosome translocation. Am J Pathol 2001; 158(6): 2089-2096
53. Argani P, Lal P, Hutchinson B, Lui MY, Reuter VE, Ladanyi M. Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay. Am J Surg Pathol 2003; 27(6): 750-761
54. Bruder E, Passera O, Harms D, et al. Morphologic and molecular characterization of renal cell carcinoma in children and young adults. Am J Surg Pathol 2004; 28(9): 1117-1132
55. Argani P, Lae M, Hutchinson B, et al. Renal Carcinomas With the t(6;11)(p21;q12): Clinicopathologic Features and Demonstration of the Specific Alpha-TFEB Gene Fusion by Immunohistochemistry, RT-PCR, and DNA PCR. Am J Surg Pathol 2005; 29(2): 230-240
56. Argani P, Olgac S, Tickoo SK, et al. Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol 2007; 31(8): 1149-1160
57. Green WM, Yonescu R, Morsberger L, et al. Utilization of a TFE3 Break-apart FISH Assay in a Renal Tumor Consultation Service. Am J Surg Pathol 2013; 37(8): 1150-1163
58. Pflueger D, Sboner A, Storz M, et al. Identification of molecular tumor markers in renal cell carcinomas with TFE3 protein expression by RNA sequencing. Neoplasia 2013; 15(11): 1231-1240
59. Malouf GG, Camparo P, Oudard S, et al. Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. Ann Oncol. 2010; 21(9): 1834-1838
60. Filho Jdo E, Meneses de Amorim D, et al. Renal epithelioid angiomyolipoma with epithelial cysts: demonstration of Melan A and HMB45 positivity in the cystic epithelial lining. Ann Diagn Pathol 2012; 16(5): 397-401
61. Bjornsson J, Short MP, Kwiatkowski DJ, Henske EP. Tuberous sclerosis-associated renal cell carcinoma. Clinical, pathological, and genetic features. Am J Pathol 1996; 149(4): 1201-1208
62. Nese N, Martignoni G, Fletcher CD, et al. Pure epithelioid PEComas (so-called epithelioid angiomyolipoma) of the kidney: A clinicopathologic study of 41 cases: detailed assessment of morphology and risk stratification. Am J Surg Pathol 2011; 35(2): 161-176
63. Martignoni G, Pea M, Rocca PC, Bonetti F. Renal pathology in the tuberous sclerosis complex. Pathology 2003; 35(6): 505-512
64. Martignoni G, Pea M, Reghellin D, Zamboni G, Bonetti F. Perivascular epithelioid cell tumor (PEComa) in the genitourinary tract. Adv Anat Pathol 2007; 14(1): 36-41
65. Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008; 358(2): 140-151
66. Haibach H, Burns TW, Carlson HE, Burman KD, Deftos LJ. Multiple hamartoma syndrome (Cowden's disease) associated with renal cell carcinoma and primary neuroendocrine carcinoma of the skin (Merkel cell carcinoma). Am J Clin Pathol 1992; 97(5): 705-712
67. Kondo K, Yao M, Kobayashi K, et al. PTEN/MMAC1/TEP1 mutations in human primary renal-cell carcinomas and renal carcinoma cell lines. Int J Cancer 2001; 91(2): 219-24
68. Dahinden C, Ingold B, Wild P, et al. Mining tissue microarray data to uncover combinations of biomarker expression patterns that improve intermediate staging and grading of clear cell renal cell cancer. Clin Cancer Res 2010; 16(1): 88-98
69. Squarize CH, Castilho RM, Gutkind JS. Chemoprevention and treatment of experimental Cowden's disease by mTOR inhibition with rapamycin. Cancer Res 2008; 68(17): 7066-7072
70. Launonen V, Vierimaa O, Kiuru M, et al. Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci USA 2001; 98(6): 3387-3392
71. Alam NA, Rowan AJ, Wortham NC, et al. Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency. Hum Mol Genet 2003; 12(11): 1241-1252
72. Tomlinson IP, Alam NA, Rowan AJ, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 2002; 30(4): 406-410
73. Morris MR, Maina E, Morgan NV, et al. Molecular genetic analysis of FIH-1, FH, and SDHB candidate tumour suppressor genes in renal cell carcinoma. J Clin Pathol 2004; 57(7): 706-711
74. Yang Y, Valera V, Sourbier C, et al. A novel fumarate hydratasedeficient HLRCC kidney cancer cell line, UOK268: a model of the Warburg effect in cancer. Cancer Genet 2012; 205(7-8): 377-390
75. Gill AJ, Pachter NS, Chou A, et al. Renal tumors associated with germline SDHB mutation show distinctive morphology. Am J Surg Pathol 2011; 35(10): 1578-1585
76. Ricketts CJ, Shuch B, Vocke CD, et al. Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer. J Urol 2012; 188(6): 2063-2071
77. Isaacs JS, Jung YJ, Mole DR, et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 2005; 8(2): 143-153
78. Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-updagger. Ann Oncol 2014; 25 Suppl 3: iii49-iii56
79. Harris DT. Hormonal therapy and chemotherapy of renal-cell carcinoma. Semin Oncol 1983; 10(4): 422-430
80. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20(1): 289-296
81. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005; (1): CD001425
82. Clement JM, McDermott DF. The high-dose aldesleukin (IL-2) "select" trial: a trial designed to prospectively validate predictive models of response to high-dose IL-2 treatment in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 2009; 7(2): E7-E9
83. Motzer RJ, Murphy BA, Bacik J, et al. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 2000; 18(16): 2972-2980
84. Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003; 21(16): 3127-3132
85. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 1998; 338(18): 1272-1278
86. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008; 26(33): 5422-5428
87. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356(2): 115-124
88. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27(22): 3584-3590
89. Motzer RJ, Hutson TE, McCann L, Deen K, Choueiri TK. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N Engl J Med 2014; 370(18): 1769-1770
90. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013; 369(8): 722-731
91. Escudier B, Porta C, Bono P, et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J Clin Oncol 2014; 32(14): 1412-1418
92. Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009; 27(20): 3312-3318
93. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011; 378(9807): 1931-1939
94. Motzer RJ, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 2013; 14(6): 552-562
95. Stenner F, Chastonay R, Liewen H, et al. A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinoma. Oncology 2012; 82(6): 333-340
96. Rini BI, Atkins MB. Resistance to targeted therapy in renal-cell carcinoma. The Lancet Oncol 2009; 10(10): 992-1000
97. Michel MS, Vervenne W, de Santis M, et al. SWITCH: A randomized sequential open-label study to evaluate efficacy and safety of Sorafenib/Sunitinib versus Sunitinib/Sorafenib in the treatment of metastatic renal cell Cancer (mRCC). J Clin Oncol 2014; 32((suppl4, abstr 393), 2014 Genitourinary Cancer Symposium):(suppl4, abstr 393), 2014 Genitourinary Cancer Symposium.
98. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17(8): 2530-2540
99. Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009; 27(34): 5794-6579
100. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356(22): 2271-2281
101. Motzer RJ, Barrios CH, Kim TM, et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol 2014; 32(25): 2765-2772
102. Powels T, Oudard S, Escudier B, et al. A radomized phase II study of GDC-0980 versus everolimus in metastatic renal cell carcinoma (mRCC) patients after VEGF-targeted therapy. J Clin Oncol 32:5s, 2014 ASCO annual meeting (suppl; abstr 4525). 2014
103. Motzer RJ, Porta C, Vogelzang NJ, et al. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncol 2014; 15(3): 286-296
104. Oudard SGG M, Geoffrois L, Guillot A, et al. Clinical Activity of Sunitinib Rechallenge in metastatic Renal Cell Carcinoma (MRCC) - Results of the RESUME Study. Ann Oncol 25(Supplement 4):Supplement 4, 39th ESMO Congress Madrid, Spain, 26-30 September 2014
105. Porta C, Paglino C, Grunwald V. Sunitinib re-challenge in advanced renal-cell carcinoma. Br J Cancer 2014; 111(6): 1047-1053
106. Motzer RJ, Nosov D, Eisen T, et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol 2013; 31(30): 3791-3799
107. Hutson TE, Lesovoy V, Al-Shukri S, et al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol 2013; 14(13): 1287-1294
108. Eisen T, Shparyk Y, Macleod N, et al. Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study. Invest New Drugs 2013; 31(5): 1283-1293
109. Tannir NM, Wong YN, Kollmannsberger CK, et al. Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure. Eur J Cancer 2011; 47(18): 2706-2714
110. Mulders P, Hawkins R, Nathan P, et al. Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study. Eur J Cancer 2012; 48(4): 527-537
111. Eisen T, Joensuu H, Nathan PD, et al. Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial. Lancet Oncol 2012; 13(10): 1055-1062
112. Choueiri TK, Pal SK, McDermott DF, et al. A phase I study of cabozantinib (XL184) in patients with renal cell cancer. Ann Oncol 2014; 25(8): 1603-1608
113. Bendell JC, Gordon MS, Hurwitz HI, et al. Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer. Clin Cancer Res 2014; 20(2): 480-489
114. Yang JC, Hughes M, Kammula U, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 2007; 30(8): 825-830
115. McDermott DF, Sznol M, Sosman JA, et al. Immune correlates and long term follow up of a phase IA study of MPDL3280A, an engineered PD-L1 Antibody, in patients with metastatic renal cell carcinoma (mRCC). Ann Oncol, 25, Supplement 4, 39th ESMO Congress Madrid, Spain, 26-30 September 2014, abstr 809O. 2014
116. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366(26): 2443-2454
117. Motzer RJR, BI, McDermott DF, Redman B, et al. Randomized Dose-ranging Phase II Trial of Nivolumab for metastatic Renal Cell Carcinoma (MRCC). Ann Oncol Supplement 4, 39th ESMO Congress Madrid, Spain, 26-30 September 2014 2014; 25(Supplement 4):Supplement 4, 39th ESMO Congress Madrid, Spain, 26-30 September 2014
118. Hammers H, Plimack ER, Infante JR, et al. Phase I Study of Nivolumab in combination with Ipilimumab in metastatic Renal Cell Carcinoma (mRCC). Ann Oncol 25 Supplement 4, 39th ESMO Congress Madrid, Spain, 26-30 September 2014, Abstract 1050O. 2014
119. Amin A, Plimack ER, Infante JR, et al. Nivolumab (Anti-PD-1; BMS-946558, ONO-4538) in Combination with Sunitinib or Pazopanib in Patients with metastatic Renal Cell Carcinoma (MRCC) Ann Oncol 25: Supplement 4, 39th ESMO Congress Madrid, Spain, 26-30 September 2014
120. Barrascout E, Beuselinck B, Ayllon J, et al. Complete remission of pulmonary metastases of Bellini duct carcinoma with cisplatin, gemcitabine and bevacizumab. Am J Case Rep 2012; 13: 1-2
121. Molina AM, Feldman DR, Ginsberg MS, et al. Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma. Invest New Drugs 2012; 30(1): 335-340
122. Tannir NM, Plimack E, Ng C, et al. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol 2012; 62(6): 1013-1019
123. Lee JL, Ahn JH, Lim HY, et al. Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma. Ann Oncol 2012; 23(8): 2108-2114
124. Choueiri TK, Plantade A, Elson P, et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008; 26(1): 127-131
125. Ravaud A, Oudard S, De Fromont M, et al. First line Sunitinib in type I and II papillary Renal Cell Carcinoma (PRCC): SUPAP- a phase II study of the Fench Genito-Urinary Group (GETUG). ESMO Congress 2012, Abstract 797PD. 2012
126. Escudier B, Bracarda S, Maroto Rey J, et al. Open-label, phase II raptor study of everolimus for papillary mRCC: Efficac in tpe 1 and type 2 histology. ASCO Genitourinary Cancer Symposium 2014, J Clin Oncol 32, (suppl 4, abstr 410). 2014
127. Koh Y, Lim HY, Ahn JH, et al. Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma. Ann Oncol 2013; 24(4): 1026-1031
128. Dutcher JP, de Souza P, McDermott D, et al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 2009; 26(2): 202-209
129. Venugopal B, Ansari J, Aitchison M, Tho LM, Campbell R and, Jones RJ. Efficacy of temsirolimus in metastatic chromophobe renal cell carcinoma. BMC Urol 2013; 13: 26
130. Armstrong AJ, Halabi S, Eisen T, et al. ASPEN: A randomized phase II trial of everolius versus sunitinib in patients with metastatic non-clear cell renal cell carcinoma. ASCO Annual meeting J Clin Oncol 31, 2013 (suppl; abstr TPS4590). 2013
131. Tannir NM, Jonasch E, Altinmakas E, et al. Everolimus versus Sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (The ESPN Trial): A multicenter randomized phase 2 trail. ASCO Annual meeting J Clin Oncol 32:5s, 2014 (suppl; abstr 4505). 2014
132. Choueiri TK, Vaishampayan U, Rosenberg JE, et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol 2013; 31(2): 181-186
133. Kroeger N, Xie W, Lee JL, et al. Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria. Cancer 2013; 119(16): 2999-3006
134. Choueiri TK, Fay AP, Gray KP, et al. PD-L1 Expression in nonclear cell renal cell carcinoma. Ann Oncol 2014; 25(11): 2178-2184.